SBP GROUP (01177) has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has entered into an exclusive strategic collaboration with GlaxoSmithKline PLC ("GSK") to accelerate the market launch of bepirovirsen in mainland China. Under the agreement, Chia Tai Tianqing will be responsible for the importation, distribution, hospital access, and promotional and non-promotional activities for bepirovirsen in mainland China, with all product sales revenue recognized as Chia Tai Tianqing's operating income. GSK will continue to serve as the Marketing Authorization Holder (MAH), overseeing regulatory affairs, quality control, pharmacovigilance, and global medical strategy. According to the terms, Chia Tai Tianqing will procure bepirovirsen from GSK under agreed supply terms during the initial 5.5-year collaboration period, after which both parties may extend the partnership by mutual agreement. The agreement also provides an opportunity for further collaboration on certain assets from the group's R&D pipeline that are seeking partnership opportunities outside China. This collaboration is expected to support the establishment of a long-term partnership between the two companies and lay a solid foundation for future expansion of innovative asset cooperation. This strategic partnership marks another instance of high recognition from a leading global multinational pharmaceutical company (MNC) for the group, following its strategic collaboration with Boehringer Ingelheim in April 2024, and successfully establishes a strategic partnership. Such collaborations not only further enrich the group's innovative product pipeline and are anticipated to significantly contribute to future revenue growth but also demonstrate the group's outstanding commercialization capabilities, extensive market access platform, and robust compliance system. By continuously deepening strategic collaborations with global leading pharmaceutical companies, the group further solidifies its industry-leading position as a preferred partner for MNCs in China.